Randomized controlled trials and real-world data: differences and similarities to untangle literature data

被引:102
|
作者
Monti, Sara [1 ]
Grosso, Vittorio [1 ]
Todoerti, Monica [1 ]
Caporali, Roberto [1 ]
机构
[1] Univ Pavia, Dept Rheumatol, IRCCS Policlin S Matteo Fdn, I-27100 Pavia, Italy
关键词
randomized controlled trial; real-world data; study design; rheumatoid arthritis; biologic drugs; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; EXTERNAL VALIDITY; INFLIXIMAB; BIOLOGICS; THERAPY; AGENT; RISK;
D O I
10.1093/rheumatology/key109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Randomized controlled trials (RCTs) represent the gold-standard of medical evidence to assess the efficacy and safety of therapeutic interventions. However, the need to minimize bias and ensure the correct design to explore the study aims often affects the generalizability of results. As a consequence, the evidence derived from the most rigorous research strategy available is not always representative of the real-world settings for which this evidence is ultimately intended. Observational studies, in contrast, although affected by a number of potential confounders, can more effectively capture treatment characteristics and safety issues that had not been identified by previous RCTs, owing to the short duration of follow-up or highly selective inclusion criteria. The aim of this review is to provide a comparative summary of the main advantages and pitfalls of RCTs and real-world data, emphasizing the need for a constant integration of all available levels of evidence to provide the best care for patients.
引用
收藏
页码:54 / 58
页数:5
相关论文
共 50 条
  • [21] The evolving role of data & safety monitoring boards for real-world clinical trials
    Bunning, Bryan J.
    Hedlin, Haley
    Chen, Jonathan H.
    Ciolino, Jody D.
    Ferstad, Johannes Opsahl
    Fox, Emily
    Garcia, Ariadna
    Go, Alan
    Johari, Ramesh
    Lee, Justin
    Maahs, David M.
    Mahaffey, Kenneth W.
    Opsahl-Ong, Krista
    Perez, Marco
    Rochford, Kaylin
    Scheinker, David
    Spratt, Heidi
    Turakhia, Mintu P.
    Desai, Manisha
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
  • [22] Adding value to real-world data: the role of biomarkers
    Plant, Darren
    Barton, Anne
    RHEUMATOLOGY, 2020, 59 (01) : 31 - 38
  • [23] Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
    Jang, Ha Young
    Kim, In-Wha
    Oh, Jung Mi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [24] Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials
    Vener, Claudia
    Rossi, Silvia
    Minicozzi, Pamela
    Marcos-Gragera, Rafael
    Poirel, Helene A.
    Maynadie, Marc
    Troussard, Xavier
    Pravettoni, Gabriella
    De Angelis, Roberta
    Sant, Milena
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Rafael Dal-Ré
    Perrine Janiaud
    John P. A. Ioannidis
    BMC Medicine, 16
  • [26] Unit information prior for incorporating real-world evidence into randomized controlled trials
    Zhang, Hengtao
    Yin, Guosheng
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2023, 32 (02) : 229 - 241
  • [27] Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Dal-Re, Rafael
    Janiaud, Perrine
    Ioannidis, John P. A.
    BMC MEDICINE, 2018, 16
  • [28] Proxy endpoints - bridging clinical trials and real world data
    Kryukov, Maxim
    Moriarty, Kathleen P.
    Villamea, Macarena
    O'Dwyer, Ingrid
    Chow, Ohn
    Dormont, Flavio
    Hernandez, Ramon
    Bar-Joseph, Ziv
    Rufino, Brandon
    JOURNAL OF BIOMEDICAL INFORMATICS, 2024, 158
  • [29] Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
    Bertoldi, Ilaria
    Caporali, Roberto
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2021, 13 : 221 - 237
  • [30] Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
    Dongwon Yoon
    Han Eol Jeong
    Sohee Park
    Seng Chan You
    Soo-Mee Bang
    Ju-Young Shin
    BMC Medicine, 21